I am glad to learn that 2 dermatologists with major responsibility for the future of one of the most important events in the world of dermatology, namely, the meeting of the EADV, share my concern about excessive sponsorship of it by pharmaceutical companies.
Nonetheless, we have still some points of difference about this matter. The figures I gave of sponsored attendants at the EADV meeting in Nice, France, in October 1998 were provided to me by the pharmaceutical industry. The fact that the companies did not formally register all sponsored dermatologists probably explains the difference between Professor Ortonne's numbers1 and those of the sponsoring companies. Even 40%, however, seems improper to me. Furthermore, it is an indication that the program of the Academy is not sufficiently substantial in itself to attract dermatologists who are willing to pay their own way.
Martino Neumann HA. In Reply. Arch Dermatol. 2000;136(3):311. doi:10.1001/archderm.136.3.311